Table 2.

Clinical factors associated with the probability of loss of MR^4.5

Variables	No. of pts	No. of events	Univariate Analysis	Multivariate analysis
Variables	No. of pts	No. of events	P	HR	95% CI	P
Age
< 65 years	87	30
≥ 65 years	13	5	0.778
Sex
Male	43	18
Female	57	17	0.160
First treatment
Interferon	32	7
TKI	68	28	0.031	0.60	0.25 to 1.44	0.249
Frontline TKI
Imatinib	43	19
Dasatinib	13	4	0.463
Nilotinib	9	2	0.439
Bosutinib	1	1	0.210
Poantinib	2	2	0.100
Last TKI before discontinuation
Imatinib	47	11
Dasatinib	35	16	0.021
Nilotinib	14	6	0.064
Bosutinib	2	1	0.604
Ponatinib	2	1	0.548
Frontline and only TKI
Imatinib	23	8
Dasatinib	13	4	0.892
Nilotinib	7	2	0.970
Line of TKI
1 line	68	18
> 2 line	32	17	0.007	1.43	0.64 to 3.19	0.377
Response at 3 months
BCR-ABL/ABL < 10% (IS)	53	18
BCR-ABL/ABL ≥ 10% (IS)	3	2	0.213
Transcript type
b3a2	50	17
b2a2	30	10	0.866
b3a2 + b2a2	17	7	0.511
Sokal score
Low	35	10
Intermediate	21	9	0.261
High	4	0	0.999
Reason for discontinuation
Elective	47	15
Adverse effects	53	20	0.557
Duration to achieve MR^4.5
< 17 months	47	15
≥ 17 months	53	20	0.593
Duration of MR^4.5
< 72 months	46	31
≥ 72 months	54	4	< 0.001	0.11	0.03 to 0.41	0.001
Duration of TKI therapy
< 87 months	34	22
≥ 87 months	66	13	< 0.001	0.73	0.29 to 1.82	0.501

CI confidence interval, HR hazard ratio, MR4.5 molecular response of 4.5-log reduction from baseline, P P value, TKI tyrosine kinase inhibitor